India, April 29 -- Caris Life Sciences (CAI), an artificial intelligence TechBio and precision medicine company, announced on Wednesday the development and peer-reviewed publication of a predictive signature for therapy selection in glioblastoma patients.
Glioblastoma (GBM) represents one of the most common and aggressive and inoperable brain malignancies, with a life expectancy of 12 months from time of diagnosis. Current treatment options include surgery, radiation, and chemotherapy by temozolomide (TMZ). But more than half of the patient population does not respond to TMZ, and develops resistance to the treatment.
The artificial intelligence (AI) model developed by Caris determines an individual patient's risk of developing resistance ...